4 results
Primary:Cohort 1: To estimate the ORR when a dose of105 mg/m2 LY2606368 every 14 days isadministered to patients with ED-SCLC that haveplatinum-sensitive disease* Cohort 2: To estimate the ORR when a dose of105 mg/m2 LY2606368 every 14 days…
The aim of this study is determine the efficacy and safety of Metformin as a weight reducing drug in the euglykemic, obese paediatric population.
Primary objectiveTo confirm the superiority of liraglutide at the maximum tolerated dose (0.6 mg, 1.2 mg or 1.8 mg) versus placebo when added to metformin with or without basal insulin treatment in controlling glycaemia in children and adolescents (…
Primary• To investigate the safety and tolerability of multiple oral doses of DNL343 in participants with ALSSecondary• To characterize the PK of DNL343 in plasma following single and multiple oral doses• To characterize the concentration of DNL343…